Site menu
Menu
Get expert investment analysis on the Australian stockmarket, economy and property from Rask Media’s chosen fund managers, selected analysts and writers. Stay up to date with your preferred experts by creating a free Rask account.
The Resmed CDI (ASX: RMD) share price is down over 30% over the past 12 months as analysts and investors weigh up the long-term impact of GLP-1 treatments on RMD’s obstructive sleep apnea (OSA) market.
Global energy markets will need to evolve dramatically over the next three decades. Worldwide, the population is forecast to grow by nearly 2 billion1 and global living standards are expected to rise as per capita consumption increases – and all this against the backdrop of a growing push towards decarbonisation.
The local share market fell for a second straight day on Tuesday, ahead of a flurry of central bank meetings, and following the release of a set of minutes from the Reserve Bank of Australia that were taken as implying that the local central bank is considered raising rates.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.47% to 7196.60.
I outline 5 of my favourite ETFs in Australia. But be aware: these ETFs won’t be right for everyone, so keep reading (and definitely read the PDS & TMD of each fund). Watch it live – Wednesday at 12 noon.
Marcus Today does Technical Scans every day, and on 15 September 2023, they turned up four big stocks (five if you include Resmed CDI (ASX: RMD), seven including resources) that are interestingly oversold on weekly charts.
Revenue for the second quarter came in at US$13.5 billion, nearly US$2 billion above the analyst consensus estimate (which un-coincidentally was almost exactly in-line with the guidance of US$11 billion provided last quarter) and a staggering 101.5% above the prior year’s results.
The local share market started the week lower, ahead of the US Federal Reserve’s two-day policy meeting, which begins on Tuesday.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.67% to 7230.40.
The Resmed CDI (ASX: RMD) share price is down over 30% over the past 12 months as analysts and investors weigh up the long-term impact of GLP-1 treatments on RMD’s obstructive sleep apnea (OSA) market.
Global energy markets will need to evolve dramatically over the next three decades. Worldwide, the population is forecast to grow by nearly 2 billion1 and global living standards are expected to rise as per capita consumption increases – and all this against the backdrop of a growing push towards decarbonisation.
The local share market fell for a second straight day on Tuesday, ahead of a flurry of central bank meetings, and following the release of a set of minutes from the Reserve Bank of Australia that were taken as implying that the local central bank is considered raising rates.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.47% to 7196.60.
I outline 5 of my favourite ETFs in Australia. But be aware: these ETFs won’t be right for everyone, so keep reading (and definitely read the PDS & TMD of each fund). Watch it live – Wednesday at 12 noon.
Marcus Today does Technical Scans every day, and on 15 September 2023, they turned up four big stocks (five if you include Resmed CDI (ASX: RMD), seven including resources) that are interestingly oversold on weekly charts.
Revenue for the second quarter came in at US$13.5 billion, nearly US$2 billion above the analyst consensus estimate (which un-coincidentally was almost exactly in-line with the guidance of US$11 billion provided last quarter) and a staggering 101.5% above the prior year’s results.
The local share market started the week lower, ahead of the US Federal Reserve’s two-day policy meeting, which begins on Tuesday.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.67% to 7230.40.
Want to level-up your analytical skills and investing insights but don’t know where to start? We can help. Join 40,000+ Australian investors on our mailing list today and we’ll send you our favourite podcasts, courses, resources, investment articles and podcasts every week. Delivered to your inbox every Sunday morning. Grab a coffee and let Owen and the team bring you the best investment insights every week.
The information on this website is general financial advice only. That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. In addition, you should obtain and read the product disclosure statement (PDS) and Target Market Determination before making a decision to acquire any financial product. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please read our Terms & Conditions and Financial Services Guide before using this website.
“Rask Invest” is considered a financial product and has a Product Disclosure Statement (PDS) and Target Market Determination (TMD), issued by InvestSMART. These documents can be accessed on the Rask Invest website. Please seek professional advice before making any investment decision with respect to Rask Invest.
© Rask Australia 2024
